On-Demand CME Videos
CMEswiper: Swiping Away Comorbidities Through the Lens of Psoriatic Disease: An Online Activity
About
CMEswiper: Swiping Away Comorbidities Through the Lens of Psoriatic Disease: An Online CME Activity
This activity is supported by educational grants from Amgen and Lilly.
Log-on to try our CMEswiper! A new, mobile-friendly format to provide 'anywhere, anytime' rapid personalized learning. ‘Swipe’ through content at your own pace in an animated micro-learning environment that focuses on key insights and clinical pearls with high focus.
‘Tap’ to gain access to additional information on a topic via pop-ups, audio clips, clinical images, and more. The CMEswiper – New format, same great interactive content!
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
August 28, 2024
August 31, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
List key therapies to manage psoriatic disease and associated comorbidities
Select optimal therapies for psoriasis patients based on demographics, comorbidities, and medical history
Intended Audience
Faculty
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.
Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.